Qian, Lei

Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight

Ji, L., Jiang, H., Bi, Y., Li, H., Tian, J., Liu, D., Zhao, Y., Qiu, W., Huang, C., Chen, L., et al. (2025) · New England Journal of Medicine

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 125

A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity

Ji, L., Jiang, H., Cheng, Z., Qiu, W., Liao, L., Zhang, Y., Li, X., Pang, S., Zhang, L., Chen, L., et al. (2023) · Nature Communications

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 118

Efficacy and safety of mazdutide in Chinese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial

Zhang, B., Cheng, Z., Chen, J., Zhang, X., Liu, D., Jiang, H., Ma, G., Wang, X., Gan, S., Sun, J., et al. (2024) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 91

Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial

Ji, L., Gao, L., Jiang, H., Yang, J., Yu, L., Wen, J., Cai, C., Deng, H., Feng, L., Song, B., et al. (2022) · eClinicalMedicine

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 83

IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study

Ji, L., Jiang, H., An, P., Deng, H., Liu, M., Li, L., Feng, L., Song, B., Han-Zhang, H., Ma, Q., et al. (2021) · EClinicalMedicine

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 63